NOVO NORDISK A/S
Commented by Armin Schulz on September 4th, 2026 | 07:35 CEST
From the Pill to the Dissolving Film and the Monthly Injection for Obesity: Novo Nordisk, BioNxt Solutions and Pfizer
Obesity treatment is undergoing a transformation. Following the initial success of GLP-1 medications, the next round is now underway. It is no longer just about efficacy, but also about the method of administration. Novo Nordisk was the first to launch the oral pill on the European market and is already testing lower maintenance doses. BioNxt Solutions is countering with oral dissolvable thin films (ODFs) that require neither a needle nor water. Pfizer, meanwhile, is focusing on a monthly ultra-long-acting GLP-1 derived through its acquisition of Metsera. Today we take a closer look at the strategies of Novo Nordisk, BioNxt Solutions and Pfizer.
Read
Commented by Matthias Schomber on August 31st, 2026 | 06:55 CEST
Market Opportunities and Contrasts: Novo Nordisk with Weight-Loss Pill, ASIC Concerns at DroneShield, Power Metallic Mines with Breakout Potential
Danish pharmaceutical giant Novo Nordisk has suffered a significant setback in the fierce race for the lucrative weight-loss drug market, but its new weight-loss pill could now prove to be a game changer. At the same time, Australian drone specialist DroneShield is facing regulatory headwinds that are severely testing investor confidence, yet the numbers remain strong. Away from these companies, Canada's resource sector has another standout in Power Metallic Mines, which is demonstrating impressively how a solid polymetallic discovery and excellent drilling results can inject strength and momentum into a stock chart performance. Read on to find out why these three stocks deserve a place on every watchlist right now!
Read
Commented by André Will-Laudien on August 25th, 2026 | 09:15 CEST
Biotech M&A Boom: Novo Nordisk & Eli Lilly Battle for Market Share — BioNxt and Evotec on the Radar
As the recent spectacular USD 43 billion acquisition of cancer specialist Seagen by Pfizer and the mega-deals surrounding the GLP-1 infrastructure impressively demonstrate, the pharmaceutical industry is in the midst of a historic wave of consolidation. Driven by the massive, billion-dollar profits from the weight-loss injection market, an unprecedented wave of acquisitions has now begun. Market leaders such as Novo Nordisk and Eli Lilly are using their well-stocked war chests to pursue strategic mega-acquisitions to secure their dominant positions and systematically eliminate production bottlenecks. At the same time, highly innovative platform companies like BioNxt are coming into focus with their novel delivery systems. Strategically valuable targets currently trading at attractive valuations, such as Evotec, have long been in the crosshairs of investors and competitors. Those who do not want to be left behind in the battle for market share, new delivery technologies, and the next generation of blockbuster drugs must make acquisitions now, because the M&A carousel is spinning faster than it has in a long time. We dig a little deeper!
Read
Commented by Carsten Mainitz on August 19th, 2026 | 07:55 CEST
Weight-Loss Boom 2.0: BioNxt Solutions, Novo Nordisk and Nestlé Are Growing in a Billion-Dollar Market
The weight-loss injection has not only transformed the pharmaceutical market but is also gradually impacting the food industry. The prescription drug semaglutide, used to treat type 2 diabetes and obesity, is at the forefront of this trend. The active ingredient mimics the body's own gut hormone GLP-1, thereby achieving several desired effects. It increases feelings of fullness, reduces appetite, slows gastric emptying, and improves insulin secretion. Meanwhile, innovative specialists such as BioNxt Solutions are positioning themselves by advancing alternative and improved drug delivery methods. The Canadian company is developing thin films of active ingredients that dissolve under the tongue and are intended to replace medications administered via injection or traditional tablets. The news flow is promising. At the same time, Nestlé is creating a new food category for people who want to lose weight using GLP-1 preparations. Who has the edge?
Read
Commented by Jens Castner on August 13th, 2026 | 08:00 CEST
Berkshire Hathaway, Novo Nordisk & Zefiro Methane: Do Good and Profit From It – Up to 250% Potential!
Berkshire Hathaway and Novo Nordisk have clearly exceeded expectations with their latest quarterly results. We take a closer look at these two heavyweights—and in the process, we also turn our attention to a small environmental services provider that, according to analysts, could offer significant potential for a tenfold return. Zefiro Methane embodies one of Warren Buffett's mottos particularly closely: do good and talk about it—or, even better, do good and make money from it.
Read
Commented by Fabian Lorenz on August 7th, 2026 | 07:20 CEST
Comeback Opportunity or Cause for Caution? Gerresheimer, Novo Nordisk, and American Atomics
Novo Nordisk shares have plummeted by about 10% in just a few trading days. This brings the pharmaceutical giant's rally, which began in April, to an end for the time being. Disappointing clinical trial results, combined with a smaller-than-expected increase to the company's full-year guidance, left investors underwhelmed. American Atomics, on the other hand, may represent a potential turnaround story. The company is working to establish an integrated value chain in the uranium sector. Given the global expansion targets for nuclear power plants, there can be little doubt that the company can expect strong demand for uranium. There are also hopes for a recovery at Gerresheimer. The sale of several business units has generated more than EUR 1 billion in proceeds for the struggling packaging specialist. Investors are now debating whether the transaction marks a genuine strategic turning point—or whether the company is simply selling valuable assets to address near-term financial challenges.
Read
Commented by André Will-Laudien on August 4th, 2026 | 09:10 CEST
"Buy the Dip" in the Life Sciences Supercycle: Gerresheimer, Vidac Pharma, Novo Nordisk, and Pfizer as Top Performers of the Future
Rising healthcare spending, an aging population, and an unprecedented depth of research are propelling the life sciences sector into a multi-year supercycle. And there are some strong players! Gerresheimer stands out as a brilliant infrastructure asset and a leading provider of high-quality primary packaging. In the field of injections and biologics, the company benefits directly from the explosion of complex therapies and GLP-1 markets. Vidac Pharma is conducting research in the field of cancer and leveraging the Warburg effect for its upcoming studies—a classic high-beta play for investors betting on above-average growth. Novo Nordisk remains the undisputed flagship of the obesity and diabetes wave, and Pfizer is using the current lull in valuations as an opportunity to ignite the next phase of growth with a broad pipeline spanning oncology, vaccines, and new forms of therapy. Who belongs in the portfolio for the next life sciences boom?
Read
Commented by André Will-Laudien on July 29th, 2026 | 07:50 CEST
Active Ingredients, Acquisitions and Spin-offs: Will Bayer, Novo Nordisk, BioNxt, or Evotec Become Top M&A Targets?
After years of consolidation, investors are asking: Will things start looking up again? The global life sciences sector is facing another massive wave of consolidation in 2026 as established pharmaceutical giants and agile biotech pioneers realign their businesses. Market dynamics remain high, but unfortunately, both sides are being exploited. So far, it has been predominantly speculative investors who are capitalizing on the current volatility. Following drastic share price losses and ongoing restructuring, the struggling Hamburg-based biotech company Evotec is increasingly in the crosshairs of financially strong acquirers seeking to acquire high-calibre drug discovery platforms at a bargain price. At the same time, BioNxt is attracting investor interest with its groundbreaking drug delivery systems and advanced clinical pipelines. Meanwhile, the market continues to speculate feverishly about a possible breakup or spin-off of individual divisions at the DAX-listed Bayer Group, which would massively increase its appeal to strategic buyers. On the other hand, Danish industry leader Novo Nordisk, driven by the sustained billion-dollar profits from its weight-loss portfolio, is acting as a financially powerful hunter in search of strategic acquisitions in the obesity and cardiovascular segments. For investors, this highly dynamic environment offers a rare opportunity to bet early on the year's hottest takeover candidates. What is the current status?
Read
Commented by Armin Schulz on July 29th, 2026 | 07:40 CEST
Billion-Dollar Markets of Obesity, Oncology, and Neurology in Focus: Novo Nordisk, Vidac Pharma, and AbbVie
The healthcare industry of the future is driven by three major megatrends: obesity, oncology, and neurology. While the market for cancer drugs is heading toward nearly USD 700 billion and Alzheimer's therapies are booming, the GLP-1 boom has only just begun and has replaced oncology as the largest driver of pipeline value. But not every company will benefit equally from this momentum. The key difference lies in strategic focus and the ability to translate scientific milestones into market success. We take a look at three companies today—Novo Nordisk, Vidac Pharma, and AbbVie—each of which embodies one of these areas.
Read
Commented by Nico Popp on July 23rd, 2026 | 07:50 CEST
Panic in the Multi-Billion-Dollar Market: Novo Nordisk and Halozyme Therapeutics Face Headwinds—BioNxt Solutions Nears a Turning Point
The global pharmaceutical market is worth hundreds of billions of dollars. Yet one of the industry's most surprising realities is that success increasingly depends not only on the active ingredient itself but also on how it is delivered. This does not refer to the cardboard box, but to the dosage form. Whenever patents expire, and blockbuster drugs face competition, innovative biotech companies seize the opportunity. New drug delivery technologies can transform well-known substances into more effective medicines, reduce side effects, and open up entirely new treatment options for patients. While established pharmaceutical giants spend vast sums defending market exclusivity, agile second-tier biotech companies are driving innovation through next-generation drug delivery platforms.
Read